Usefulness of genetic tests in familial hypocalciuric hypercalcemia with atypical clinical presentation

Ignacio Fernández López a,*, Ignacio Fernández Peña b, Maria Victoria Cózar León a, María Mar Viloria Peñas c, Guillermo Martínez De Pinillos Gordillo a, Mariana Tomé Fernández-Ladreda a, Santiago Duran García a

a Unidad de Gestión Clínica, Endocrinología y Nutrición, Hospital Universitario Virgen de Valme, Sevilla, Spain
b Unidad de Gestión Clínica, Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain
c Unidad de Gestión Clínica, Laboratorio Clínico, Hospital Universitario Virgen de Valme, Sevilla, Spain

Received 25 January 2011; accepted 17 April 2011

KEYWORDS
Familial hypocalciuric hypercalcemia;
Genetic tests;
Clinical presentation

Abstract
Objectives: Biochemical tests related to calcium and phosphorus metabolism have traditionally been considered as a reliable tool to differentiate familial hypocalciuric hypercalcemia (FHH) from primary hyperparathyroidism (PHPT). However, diagnosis may sometimes be difficult even for experienced clinicians. Our objective was to assess the accuracy of diagnostic tests in FHH and the circumstances in which genetic studies are required.

Patients and methods: A descriptive study was conducted of two families with hypercalcemia and suspected atypical FHH. Urinary calcium excretion was measured in 24-h urine using different tests (calcium excretion (CE), urinary calcium/creatinine clearance ratio (UCCR)), and serum PTH and 25-hydroxyvitamin D levels were tested. Index cases underwent genetic study.

Results: One patient from the first family showed overt, persistent hypercalciuria with values more consistent with PHPT than with FHH if we consider, as proposed by guidelines, a UCCR lower than 0.01 as diagnostic of FHH and a value higher than 0.02 as diagnostic of PHPT. The index case of the second family underwent surgery for a parathyroid adenoma. Both cases had a mutation c. 164C>T (Pro55Leu) in heterozygosis.

Conclusions: According to current clinical guidelines, definitive diagnosis of FHH requires genetic confirmation, which allowed in our case for detection of two families with FHH and atypical clinical presentations. We think that rational use of genetic tests may avoid unnecessary surgery and excess monitoring costs.

© 2011 SEEN. Published by Elsevier España, S.L. All rights reserved.
Introduction

Familial hypercalcemia is not uncommon in endocrinology offices. It is a hereditary disorder with an autosomal dominant transmission in most cases covering a spectrum of diseases including multiple endocrine neoplasia type 1 and 2 (MEN 1 and 2), hyperparathyroidism associated to jaw tumor, isolated familial hyperparathyroidism, and familial hypocalciuric hypercalcemia (FHH). Differentiation of the five syndromes is sometimes difficult, but has profound implications for the patient and his/her family.

Availability of specific genetic tests has improved diagnostic accuracy and simplified monitoring, but these tests are costly and often not easily accessible, and therefore require a rational use.

Inactivating mutations in the calcium-sensing receptor gene (CaSR), located in the long arm of chromosome 3, may affect a single allele (heterozygosis), which results in the phenotype characteristic of FHH, or both alleles (homozygosis or compound heterozygosis if no consanguinity exists), which leads to severe neonatal hyperparathyroidism, so that the grade of gene defect accounts for the great disparity in phenotypic presentation.

Some 200 different mutations have been reported in FHH. The end result of such mutations is a decreased number of functional receptors in parathyroid cells and kidney, which makes them partially resistant to calcium, so that high calcium levels are required to decrease PTH and calcium and magnesium are reabsorbed in the kidney even in the presence of hypercalcemia. FHH therefore causes persistent hypercalcemia, hypocalciuria which is either absolute (typically less than 200 mg/day) or relative to plasma calcium (urinary calcium/creatinine clearance ratio [UCCR] less than 0.01), and normal PTH levels, although 20% of patients have elevated PTH levels. FHH is a disorder which is considered to be benign and asymptomatic and does not appear to shorten life expectancy, but chondrocalcinosis has been reported in some adults and may confer an increased susceptibility to pancreatitis. It is important to distinguish this condition from primary hyperparathyroidism (PHPT), which is usually easy in the typical cases of both conditions because surgery is unnecessary and ineffective in FHH.

The clinical spectrum of mutations in the calcium-sensing receptor is being widened with the genetic study, and hypercalcemia, stones and, exceptionally, parathyroid adenoma have been reported in patients with FHH.

Patients and methods

This was a descriptive study of two families from the same geographic area but with no common known family history which had shown hypercalcemia during years of follow-up and in which a genetic study had recently confirmed the presence of FHH, despite their discordant clinical and biochemical data.

The index cases of the first family, with four affected members, was a 35-year-old woman 54.4 kg in weight and 158 cm in height and with a body mass index (BMI) of 21 kg/m² in whom laboratory tests performed for a
headache detected increased calcium levels (11.1 mg/dL), slightly decreased phosphorus levels (2.4 mg/dL), and normal magnesium and creatinine levels. Other test results included 24-h urinary calcium of 272 mg, tubular phosphate reabsorption (TPR) of 70%, urinary calcium/creatinine clearance ratio (UCCR) of 0.0137, elevated intact PTH levels (110 pg/mL), and 25-hydroxyvitamin D deficiency (24.8 nmo/L). parathyroid ultrasonography and a Tc-sestamibi scan showed no enlargement of parathyroid glands, adenoma, or ectopic tumors. Abdominal ultrasonography was normal, as was bone densitometry of the spine, showing a T score of –0.02 and a Z score of 0.50.

Family study revealed asymptomatic hypercalcemia in the 70-year-old father of the woman and in her two sons, aged 18 and 12 years. Soon after diagnosis, the eldest son experienced repeated episodes of renal colic and gross hematuria but passed no stones, which were not visible in standard abdominal X-rays. He attended the emergency room of our hospital for that reason in 2004, 2008, and 2010.

In the second family, the index case was a 39-year-old male 92 kg in weight and 173 cm in height (BMI, 30.7 kg/m²) in whom hypercalcemia was discovered during work-up for hypertipidemia. Further investigation revealed hypercalcemia in two of four brothers, including the index case, and also in the mother and one uncle. Initial laboratory tests showed 11.7 mg/dL of calcium, 2.74 mg/dL of phosphorus, and 2.19 mg/dL of magnesium. Urinary calcium levels were 82 mg/24 h, UCCR 0.003, urinary phosphate levels 1.254 mg/24 h, and TPR, 80%. Intact PTH was elevated (72 pg/mL) and 25-hydroxyvitamin D levels were decreased (40 nmol/L [normal range, 50–250]). Bone densitometry showed spine osteopenia (T score –1.30 and Z score –1.20). Thyroid ultrasonography was normal, but a Tc-sestamibi scan showed pathological retention of the radiotracer in the lower portion of left thyroid lobe consistent with a parathyroid adenoma in the left inferior parathyroid gland.

Calcium phosphorus, magnesium, alkaline phosphatase, and creatinine were measured in fasting conditions using a Cobas c711 Hitachi analyzer (Roche Diagnostics). Calcium and phosphate levels and TPR were tested in 24-h urine while patients were taking an unrestricted diet, and diuretic use by patients was ruled out. The three most commonly used indices of urinary calcium excretion were assessed, defining hypercalcuria as calcium excretion (CE) greater than 4 mg/kg/24 h or 240 mg in females and 300 mg in males or a calcium/creatinine ratio (CR) greater than 0.2 mg/kg. A UCCR (calcium in 24-h urine × serum creatinine/serum calcium × urinary creatinine) less than 0.01 was considered indicative of hypocalcuria.

Chemoluminescence (Innulite 2000, Siemens) was used to measure intact PTH (normal range, 11–67 pg/mL) and 25-hydroxyvitamin D (normal range, 50–250 nmol/L) levels. Vitamin levels less than 25 nmol/L were considered indicative of severe deficiency, while levels ranging from 25 to 50 nmol/L and from 50 to 75 nmol/L were, respectively defined as insufficient and suboptimal in Andalusia(10).

Table 1 shows the basic descriptive laboratory variables in the eight years of follow-up of the index case of the first family.

As shown by 24-h calcium elimination, our patient had frank, persistent hypercalcuria over time if CE and CR are considered. Assessment of UCCR results revealed intermediate values, and some clearly suggesting PHPT rather than FHH.

These high urinary calcium levels also coincide with an associated deficiency of vitamin D, whose concentration modulates the severity of the condition by causing an additional decrease in urinary calcium and often justifying the increased PTH levels seen in FHH and found in our patient.

Unlike her, her two sons have shown hypocalcicuriacal hypocalcemia since 1996, with UCCR below or very slightly above 0.01. The youngest son has remained symptom-free and with normal 25-hydroxyvitamin D levels (80 nmol/L). The eldest son experienced in 2005 three episodes of renal colic requiring treatment at the emergency room. He had at the time a plasma calcium level of 11.7 mg/dL, a phosphorus level of 3.17 mg/dL, 24-h urine CE of 248 mg, UCCR of 0.0123, an inappropriately elevated PTH level of 84 pg/mL, and a decreased 25-hydroxyvitamin D value of 49 nmol/L. Abdominal and cervical ultrasonography and Tc-sestamibi scan were normal. Exploratory surgery with subtotal parathyroidectomy was performed, but no pathological changes were found in parathyroid glands, and hypercalcemia persisted after surgery. Oxalate and citrate levels in 24-h urine were normal, but uric acid excretion was persistently elevated (up to 1542 mg/24 h), which may suggest the presence of uric stones, but patient has not passed to date stones amenable to analysis.

Because of the discordant data in this family, genetic study of the index case was performed in 2010, revealing the c. 164C>T (Pro55Leu) mutation in exon 2, which has been reported to be responsible for FHH.

In the index case of the second family, patient age, calcium concentrations, osteopenia, and scan uptake led to also perform exploratory surgery in the neck, with hypocalcuria being explained by his low vitamin D levels. An adenoma in the left inferior parathyroid gland was resected at surgery, and PTH levels decreased from 72 pg/mL...
in up to 30% of families, which may be due in some cases to 
de novo mutation may occur. No CaSR mutations are found 
families with recessive inheritance have been reported,11 or 
FHH is highly unlikely,11 but cannot be ruled out because 
 index case. If an individual subject has no affected relatives, 
gives less false positive results than a genetic study in an 
ment in blood and urine from three members of a family 
calcium measure-

<table>
<thead>
<tr>
<th>Years of follow-up</th>
<th>Calcium (mg/dL)</th>
<th>Phosphorus (mg/dL)</th>
<th>Magnesium (mg/dL)</th>
<th>PTH (pg/mL)</th>
<th>Calcium in 24-h urine (mg/24h)</th>
<th>Calcium/creatine ratio in 24-h urine</th>
<th>UCCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>11.1</td>
<td>2.4</td>
<td>0.86</td>
<td>110</td>
<td>272</td>
<td>0.18</td>
<td>0.014</td>
</tr>
<tr>
<td>2</td>
<td>10.8</td>
<td>3.0</td>
<td>0.78</td>
<td>81</td>
<td>240</td>
<td>0.27</td>
<td>0.019</td>
</tr>
<tr>
<td>3</td>
<td>10.6</td>
<td>2.11</td>
<td>0.69</td>
<td>43</td>
<td>391</td>
<td>0.57</td>
<td>0.036</td>
</tr>
<tr>
<td>4</td>
<td>11.7</td>
<td>2.62</td>
<td>0.60</td>
<td>78</td>
<td>550</td>
<td>0.38</td>
<td>0.019</td>
</tr>
<tr>
<td>5</td>
<td>10.4</td>
<td>2.46</td>
<td>0.60</td>
<td>61</td>
<td>323</td>
<td>0.26</td>
<td>0.015</td>
</tr>
<tr>
<td>6</td>
<td>11.5</td>
<td>2.69</td>
<td>0.65</td>
<td>49</td>
<td>502</td>
<td>0.39</td>
<td>0.022</td>
</tr>
<tr>
<td>7</td>
<td>11.1</td>
<td>2.79</td>
<td>0.57</td>
<td>62</td>
<td>405</td>
<td>0.35</td>
<td>0.018</td>
</tr>
<tr>
<td>8</td>
<td>11.8</td>
<td>2.8</td>
<td>0.60</td>
<td>93</td>
<td>332</td>
<td>0.33</td>
<td>0.017</td>
</tr>
</tbody>
</table>

UCCR: urinary calcium/creatinine clearance ratio.

during surgery to 47 pg/mL after the procedure. Although total calcium level normalized the day after surgery to 
9.8 mg/dL, patient continued to show hypocalciuric hyper-
calcemia (UCCR less than 0.01 at all times) at subsequent 
annual follow-up visits to our clinic despite normalization of 
vitamin D levels after treatment. Results at the last follow-
up included: calcium 11.5 mg/dL, phosphorus 1.96 mg/dL, 
magnesium 2.3 mg/dL, UCCR 0.009, 25-hydroxyvitamin D 
120 nmol/L, and PTH 34.8 pg/mL.

All other three members of the family remained 
symptom-free and had UCCR values also lower than 0.01 
during the years of follow-up.

Based on discordant history data, surgery for parathyroid 
adenoma, and family data of hypocalciuric hypercalcemia, 
a genetic study was recently requested and also showed the 
c. 164C>T (Pro55Leu) mutation in exon 2 in heterozygosis 
reported to be responsible for FHH.

Discussion

In recent years, availability of genetic tests has allowed for 
finding families with heterozygous mutations in the CaSR 
gene which show clinical features characteristic of hyper-
parathyroidism such as hypercalciuria, kidney stones and, 
more rarely, parathyroid adenoma. We monitored for years 
two families, with eight affected members, with suspected 
FHH. This was recently confirmed by genetic testing, but 
two of the patients were found to have a discordant course, 
consisting of sustained hypercalciuric hypercalcemia in one 
of them and parathyroid adenoma in the other.

Familial hypercalcemia follows an autosomal dominant 
pattern of inheritance, and is therefore diagnosed in fam-
ilies with several affected members, many of them young. 
When patients have asymptomatic hypercalcemia with rel-
ate hypercalciuria, especially if there is a history of 
infective parathyroid surgery, urinary and plasma levels 
should be investigated in several generations of relatives 
even if they are apparently unaffected. Calcium measure-
ment in blood and urine from three members of a family 
gives less false positive results than a genetic study in an 
index case. If an individual subject has no affected relatives, 
FHH is highly unlikely,11 but cannot be ruled out because 
families with recessive inheritance have been reported,11 or 
de novo mutation may occur. No CaSR mutations are found 
in up to 30% of families, which may be due in some cases to 

preference of mutations in other regions (promoter, introns, 
etc.) or implication of other different genes.

The fact that genetic tests are not indispensable because 
of the benign nature of the condition, their cost, their high 
false negative rate, and their difficult accessibility for clin-
icians until recently have limited their routine use in FHH. 
They may, however, prevent unnecessary surgery and sub-
stantial expenses in doubtful cases.12

Most cases of FHH and familial PHPT do not usually 
pose problems in differential diagnosis, but both diseases 
have atypical presentations difficult to differentiate. Thus, 
normal PTH levels are found in 10% of PHPT, and high 
PTH levels are seen in 15–20% of patients with FHH. The 
guidelines12 propose cut-off points for UCCR of less than 
0.01 for diagnosis of FHH and more than 0.02 for diagno-
sis of PHPT, which are widely quoted and accepted.13 A 
study14 recently assessed the discriminating power of the 
three renal indices and established an optimum cut-off point 
of 0.0115, but there may be overlapping in urinary calcium 
excretion between the two conditions.

A decreased renal calcium excretion, with a UCCR even 
less than 0.001, may be found in some patients with PHPT, 
especially if they also have vitamin D deficiency, which is 
currently so common in Spain and Andalusia as to be con-
sidered an epidemic,15–17 and patients with FHH may have 
hypercalcemia or, more rarely, stones,1,8 which causes diag-
nostic errors even in the hands of experienced clinicians.

Twenty percent of cases of FHH and up to 12% of those of 
PHPT would be inadequately classified and potentially mis-
treated, even if the cut-off point for UCCR is increased from 
less than 0.01 to 0.0115. A two-step diagnostic approach 
has therefore been suggested13 for doubtful cases. UCCR is 
first determined using a cut-off value of less than 0.020. 
This excludes two thirds of PHPTs, which will have a higher 
value, and will include 98% of FHHs. The next step would be 
to determine the CaSR gene in families with UCCR less than 
0.020, which separates patients with mutations (FHH) from 
those with mutations (PHPT).

A potential cause of error is not assessing concentra-
tions of vitamin D, which is indispensable in these patients 
because its deficiency causes decreased intestinal absorp-
tion and renal excretion of calcium, increased PTH levels, 
and inactivation of the calcium-sensing receptor.18 Patients 
with PHPT appear to have lower 25-hydroxyvitamin D lev-
 els as compared to controls, and renal calcium excretion in 
these patients positively correlates to these levels, reaching 
in patients with deficiency levels typical of FHH.10,19
Usefulness of genetic tests in familial hypocalciuric hypercalcemia

On the other hand, it should be noted that intensity of the CaSR gene mutation is variable and conditions the extent of PTH secretion, tubular calcium reabsorption, and calcemia in an individual patient.

Our two index cases from both families with FHH had decreased levels of 25-hydroxyvitamin D. In one of them, vitamin D replacement therapy decreased PTH levels but, as reported in patients with FHH, did not change renal calcium excretion, which continued to be very low (UCCR less than 0.01). Absence of a sustained increase in PTH in patients with FHH contributes to its usually benign course and to the absence of bone involvement.

One of the patients had sustained hypercalciuria, despite the associated vitamin D deficiency, with UCCR values higher than 0.02 for years of follow-up, which is exceptional. One of her sons had repeated renal colic associated to hypercalciuria and high uric acid levels in urine.

At least 9% of cases with persistent hypercalciuria following ineffective surgery are patients not diagnosed with FHH. Pathological examination of parathyroid glands showed a slight enlargement or mild hyperplasia, but no nodularity is usually found. We report a genetically proven case of FHH in which a TC-sestamibi scan revealed a left inferior parathyroid adenoma which was confirmed at surgery. This technique has an 85–100% sensitivity for localizing adenoma before surgery, and a specificity close to 100% if there is no concurrent thyroid involvement, as occurred in our case.

It is unknown whether FHH is a risk factor for subsequent development of PHPT. Expression of CaSR protein is often reduced in adenomas from patients with PHPT. One may therefore speculate that total or partial loss of receptor function may stimulate proliferation of parathyroid cells. Association of homozygous inactivating CaSR mutations to PHPT due to multiple parathyroid adenomas and severe persistent hypercalcemia after surgery has recently been reported, suggesting that loss of receptor function may occasionally induce PHPT in adults. Both diseases may rarely occur together. A search in Medline found that four cases of parathyroid adenoma in patients with genetically proven FHH have been reported in the past 10 years. This could be a simple coincidence, as PHPT is a common disease, but presence of parathyroid adenomas in different generations of one of our families does not appear to be due to chance.

25-Hydroxyvitamin D deficiency in PHPT is associated to more aggressive evolution with greater bone involvement, and new guidelines therefore recommend vitamin D replacement.

For some authors, vitamin D deficiency may have a role in development of parathyroid adenoma, and they suggest that chronic deficiency accelerates adenoma growth and that vitamin D supplementation may reverse this process by acting upon the normal allele of FHH patients, but conflicting data are available.

To sum up, availability of genetic studies is allowing for expanding the clinical spectrum of FHH. For current clinical guidelines, final diagnosis of FHH requires genetic testing. We analyzed the current genetic screening protocols in patients with suspected FHH for rational use. A genetic test for the CaSR mutation in atypical cases, such as the ones reported here, may prevent unnecessary surgery and, in our opinion, excess follow-up costs.

Conflicts of interest

The authors state that they have no conflicts of interest.

References


